| Ocular Hypertension
Alphagan P vs Rhopressa
Side-by-side clinical, coverage, and cost comparison for ocular hypertension.Deep comparison between: Alphagan P vs Rhopressa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRhopressa has a higher rate of injection site reactions vs Alphagan P based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rhopressa but not Alphagan P, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alphagan P
Rhopressa
At A Glance
Ophthalmic
Three times daily
Alpha-2 adrenergic receptor agonist
Ophthalmic (eye drop)
Once daily (evening)
Rho kinase inhibitor
Indications
- Glaucoma, Open-Angle
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) three times daily, approximately 8 hours apart; if used with other topical ophthalmic products, instill at least 5 minutes apart.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; when used concomitantly with other topical ophthalmic products to lower IOP, administer each product at least 5 minutes apart.
Contraindications
- Neonates and infants (pediatric patients younger than 2 years old)
- Previous hypersensitivity reaction to any component of ALPHAGAN P
—
Adverse Reactions
Most common (>=10%) Allergic conjunctivitis, conjunctival hyperemia, eye pruritus
Serious Potentiation of vascular insufficiency, severe cardiovascular disease
Postmarketing Bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions, syncope, tachycardia
Most common (>=20%) Conjunctival hyperemia, corneal verticillata, instillation site pain, conjunctival hemorrhage
Common (5-10%) Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, reduced visual acuity
Postmarketing Epithelial corneal edema in patients with pre-existing corneal stromal edema or following ocular procedures affecting corneal endothelial function
Pharmacology
Brimonidine tartrate is a relatively selective alpha-2 adrenergic receptor agonist that lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow, with a peak ocular hypotensive effect at approximately 2 hours post-dosing.
Netarsudil is a rho kinase inhibitor believed to reduce intraocular pressure by increasing the outflow of aqueous humor through the trabecular meshwork; the exact mechanism is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alphagan P
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Rhopressa
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (6/12) · Qty limit (9/12)
UnitedHealthcare
Alphagan P
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Rhopressa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (4/8)
Humana
Alphagan P
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Rhopressa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Alphagan P.
No savings programs available for Rhopressa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Alphagan PView full Alphagan P profile
RhopressaView full Rhopressa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.